- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Dove launches new bone densitometer
Dove Medical Systems has introduced a new bone densitometer inits OsteoAnalyzer line that is designed to provide low-cost bonemineral density exams. The system, SXA 3000, sells for under $20,000and measures bone density in the heel at the push of a
Dove Medical Systems has introduced a new bone densitometer inits OsteoAnalyzer line that is designed to provide low-cost bonemineral density exams. The system, SXA 3000, sells for under $20,000and measures bone density in the heel at the push of a singlebutton, according to the Newbury Park, CA, company.
Earlier this year, Dove signed a deal with Merck in which thatpharmaceutical firm will provide equipment financing support forphysicians purchasing Dove bone densitometers. Merck, which ismarketing its Fosamax drug for the treatment of osteoporosis,has signed similar deals with a number of other bone densitometryvendors (SCAN 2/14/96 and 7/6/95).
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
